The global synthetic biology market size is calculated at USD 24.58 billion in 2025 and is forecasted to reach around USD 192.95 billion by 2034, accelerating at a CAGR of 28.63% from 2025 to 2034. The North America synthetic biology market size surpassed USD 7.92 billion in 2024 and is expanding at a CAGR of 27.92% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Synthetic Biology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Synthetic Biology Market, by Technology
8.1.1. PCR Technology
8.1.1.1. Market Revenue and Forecast
8.1.2. NGS Technology
8.1.2.1. Market Revenue and Forecast
8.1.3. Bioprocessing Technology
8.1.3.1. Market Revenue and Forecast
8.1.4. Genome Editing Technology
8.1.4.1. Market Revenue and Forecast
8.1.5. Other Technologies
8.1.5.1. Market Revenue and Forecast
9.1. Synthetic Biology Market, by Product
9.1.1. Enzymes
9.1.1.1. Market Revenue and Forecast
9.1.2. Oligonucleotide/Oligo Pools and Synthetic DNA
9.1.2.1. Market Revenue and Forecast
9.1.3. Xeno-Nucleic Acids
9.1.3.1. Market Revenue and Forecast
9.1.4. Cloning Technologies Kits
9.1.4.1. Market Revenue and Forecast
9.1.5. Chassis Organism
9.1.5.1. Market Revenue and Forecast
10.1. Synthetic Biology Market, by Application
10.1.1. Healthcare
10.1.1.1. Market Revenue and Forecast
10.1.2. Non-healthcare
10.1.2.1. Market Revenue and Forecast
11.1. Synthetic Biology Market, by End-Use
11.1.1. Academic and Government Research Institutes
11.1.1.1. Market Revenue and Forecast
11.1.2. Biotechnology and Pharmaceutical Companies
11.1.2.1. Market Revenue and Forecast
11.1.3. Others
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Technology
12.1.2. Market Revenue and Forecast, by Product
12.1.3. Market Revenue and Forecast, by Application
12.1.4. Market Revenue and Forecast, by End-Use
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Technology
12.1.5.2. Market Revenue and Forecast, by Product
12.1.5.3. Market Revenue and Forecast, by Application
12.1.5.4. Market Revenue and Forecast, by End-Use
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Technology
12.1.6.2. Market Revenue and Forecast, by Product
12.1.6.3. Market Revenue and Forecast, by Application
12.1.6.4. Market Revenue and Forecast, by End-Use
12.2. Europe
12.2.1. Market Revenue and Forecast, by Technology
12.2.2. Market Revenue and Forecast, by Product
12.2.3. Market Revenue and Forecast, by Application
12.2.4. Market Revenue and Forecast, by End-Use
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Technology
12.2.5.2. Market Revenue and Forecast, by Product
12.2.5.3. Market Revenue and Forecast, by Application
12.2.5.4. Market Revenue and Forecast, by End-Use
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Technology
12.2.6.2. Market Revenue and Forecast, by Product
12.2.6.3. Market Revenue and Forecast, by Application
12.2.6.4. Market Revenue and Forecast, by End-Use
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Technology
12.2.7.2. Market Revenue and Forecast, by Product
12.2.7.3. Market Revenue and Forecast, by Application
12.2.7.4. Market Revenue and Forecast, by End-Use
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Technology
12.2.8.2. Market Revenue and Forecast, by Product
12.2.8.3. Market Revenue and Forecast, by Application
12.2.8.4. Market Revenue and Forecast, by End-Use
12.3. APAC
12.3.1. Market Revenue and Forecast, by Technology
12.3.2. Market Revenue and Forecast, by Product
12.3.3. Market Revenue and Forecast, by Application
12.3.4. Market Revenue and Forecast, by End-Use
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Technology
12.3.5.2. Market Revenue and Forecast, by Product
12.3.5.3. Market Revenue and Forecast, by Application
12.3.5.4. Market Revenue and Forecast, by End-Use
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Technology
12.3.6.2. Market Revenue and Forecast, by Product
12.3.6.3. Market Revenue and Forecast, by Application
12.3.6.4. Market Revenue and Forecast, by End-Use
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Technology
12.3.7.2. Market Revenue and Forecast, by Product
12.3.7.3. Market Revenue and Forecast, by Application
12.3.7.4. Market Revenue and Forecast, by End-Use
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Technology
12.3.8.2. Market Revenue and Forecast, by Product
12.3.8.3. Market Revenue and Forecast, by Application
12.3.8.4. Market Revenue and Forecast, by End-Use
12.4. MEA
12.4.1. Market Revenue and Forecast, by Technology
12.4.2. Market Revenue and Forecast, by Product
12.4.3. Market Revenue and Forecast, by Application
12.4.4. Market Revenue and Forecast, by End-Use
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Technology
12.4.5.2. Market Revenue and Forecast, by Product
12.4.5.3. Market Revenue and Forecast, by Application
12.4.5.4. Market Revenue and Forecast, by End-Use
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Technology
12.4.6.2. Market Revenue and Forecast, by Product
12.4.6.3. Market Revenue and Forecast, by Application
12.4.6.4. Market Revenue and Forecast, by End-Use
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Technology
12.4.7.2. Market Revenue and Forecast, by Product
12.4.7.3. Market Revenue and Forecast, by Application
12.4.7.4. Market Revenue and Forecast, by End-Use
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Technology
12.4.8.2. Market Revenue and Forecast, by Product
12.4.8.3. Market Revenue and Forecast, by Application
12.4.8.4. Market Revenue and Forecast, by End-Use
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Technology
12.5.2. Market Revenue and Forecast, by Product
12.5.3. Market Revenue and Forecast, by Application
12.5.4. Market Revenue and Forecast, by End-Use
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Technology
12.5.5.2. Market Revenue and Forecast, by Product
12.5.5.3. Market Revenue and Forecast, by Application
12.5.5.4. Market Revenue and Forecast, by End-Use
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Technology
12.5.6.2. Market Revenue and Forecast, by Product
12.5.6.3. Market Revenue and Forecast, by Application
12.5.6.4. Market Revenue and Forecast, by End-Use
13.1. Codexis, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bota Biosciences Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Creative Enzymes.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Creative Biogene.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Illumina, Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Enbiotix, Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. New England Biolabs
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Merck Kgaa (Sigma-Aldrich Co. Llc)
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Novozymes
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Euro fins Scientific
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample